CR20170121A - Compuestos de anamorelina y sus usos - Google Patents

Compuestos de anamorelina y sus usos

Info

Publication number
CR20170121A
CR20170121A CR20170121A CR20170121A CR20170121A CR 20170121 A CR20170121 A CR 20170121A CR 20170121 A CR20170121 A CR 20170121A CR 20170121 A CR20170121 A CR 20170121A CR 20170121 A CR20170121 A CR 20170121A
Authority
CR
Costa Rica
Prior art keywords
anamorelin
cancer
therapeutically effective
anamoreline
compounds
Prior art date
Application number
CR20170121A
Other languages
English (en)
Inventor
Suzan Allen
Enrico Baroni
William Polvino
Elizabeth Duus
Ming Lu
Ruben Giorgino
William Mann
John Friend
Original Assignee
Helsin Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55436476&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20170121(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Helsin Healthcare Sa filed Critical Helsin Healthcare Sa
Publication of CR20170121A publication Critical patent/CR20170121A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nutrition Science (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Se describen métodos de tratamiento de afecciones relacionadas con el cáncer usando anamorelina. La modalidad principal se relaciona con la afección única de pacientes que la definen mediante el tratamiento de la caquexia en un paciente humano con cáncer, que comprende la administración a dicho paciente de una cantidad terapéuticamente efectiva de anamorelina durante un período terapéuticamente efectivo, y la sorprendente capacidad observada de la anamorelina de aumentar la masa corporal magra de esta población.
CR20170121A 2014-09-04 2015-08-28 Compuestos de anamorelina y sus usos CR20170121A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462045976P 2014-09-04 2014-09-04
PCT/US2015/047435 WO2016036598A1 (en) 2014-09-04 2015-08-28 Medical treatments based on anamorelin

Publications (1)

Publication Number Publication Date
CR20170121A true CR20170121A (es) 2017-07-17

Family

ID=55436476

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20170121A CR20170121A (es) 2014-09-04 2015-08-28 Compuestos de anamorelina y sus usos

Country Status (44)

Country Link
US (5) US9675600B2 (es)
EP (2) EP3188599B1 (es)
JP (3) JP6356907B2 (es)
KR (3) KR102234319B1 (es)
CN (5) CN107375285A (es)
AP (1) AP2017009772A0 (es)
AR (1) AR103118A1 (es)
AU (1) AU2015312231B2 (es)
BR (1) BR112017003552A2 (es)
CA (1) CA2959158A1 (es)
CL (1) CL2017000494A1 (es)
CO (1) CO2017003263A2 (es)
CR (1) CR20170121A (es)
CY (1) CY1122746T1 (es)
DK (1) DK3188599T3 (es)
DO (1) DOP2017000055A (es)
EA (1) EA035578B1 (es)
EC (1) ECSP17019893A (es)
ES (1) ES2761777T3 (es)
GE (2) GEAP201814459A (es)
HR (1) HRP20192345T1 (es)
HU (1) HUE046894T2 (es)
IL (1) IL250692B (es)
JO (1) JO3541B1 (es)
LT (1) LT3188599T (es)
MA (1) MA40607B1 (es)
MD (1) MD4710C1 (es)
ME (1) ME03597B (es)
MX (1) MX361741B (es)
MY (1) MY187167A (es)
NI (1) NI201700024A (es)
PE (1) PE20171109A1 (es)
PH (1) PH12017500392B1 (es)
PL (1) PL3188599T3 (es)
PT (1) PT3188599T (es)
RS (1) RS59751B1 (es)
SG (1) SG11201701567UA (es)
SI (1) SI3188599T1 (es)
SV (1) SV2017005400A (es)
TN (1) TN2017000040A1 (es)
TW (1) TWI639429B (es)
UA (1) UA120765C2 (es)
UY (1) UY36286A (es)
WO (1) WO2016036598A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9492535B2 (en) 2013-03-14 2016-11-15 Aimmune Therapeutics, Inc. Peanut formulations and uses thereof
DK3188599T3 (da) 2014-09-04 2019-11-25 Helsinn Healthcare Sa Medicinske behandlinger baseret på anamorelin
EP3836801A4 (en) 2018-08-16 2022-05-18 Société des Produits Nestlé S.A. MAINTENANCE DOSE ORAL PEANUT IMMUNOTHERAPY
JP2022514645A (ja) 2018-12-20 2022-02-14 アイミューン セラピューティクス，インコーポレイテッド ピーナツ経口免疫療法において投与が欠落した場合の投与スケジュール
CN113966229A (zh) 2019-05-10 2022-01-21 爱沐疗法公司 用于改善花生过敏患者的生活质量的方法
CN115569120A (zh) 2019-08-30 2023-01-06 赫尔森保健股份公司 具有改善稳定性的阿拉莫林片剂的生产方法
BR112022005457A2 (pt) * 2019-10-24 2022-06-21 Toray Industries Agente terapêutico ou profilático para caquexia
JP2024534464A (ja) * 2021-09-17 2024-09-20 小野薬品工業株式会社 食欲不振／悪液質患者における患者報告アウトカムに関する臨床的に意味のある改善を判定し、提供する方法
JPWO2025004650A1 (es) * 2023-06-28 2025-01-02

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303620B1 (en) 1998-05-11 2001-10-16 Novo Nordisk A/S Compounds with growth hormone releasing properties
ECSP993020A (es) 1999-06-16 1999-08-12 Terapia de combinacion para la fragilidad musculoesqueletica
ECSP993021A (es) 1999-06-16 1999-08-12 Combinaciones terapeuticas para la fragilidad musculoesqueletica
US20010020012A1 (en) 2000-02-01 2001-09-06 Andersen Maibritt Bansholm Use of compounds for the regulation of food intake
CN1863550A (zh) * 2003-08-06 2006-11-15 加斯特罗泰克药物公司 促分泌素样生长素释放肽在癌症恶病质中以及在刺激食欲方面的应用
EP1660117A2 (en) * 2003-08-06 2006-05-31 Gastrotech Pharma A/S Use of secretagogues like ghrelin in cancer cachexia and for stimulating appetite
EP1735055A1 (en) 2004-03-30 2006-12-27 Sapphire Therapeutics, Inc. Method of reducing c-reactive protein using growth hormone secretagogues
EP2298760B1 (en) * 2004-06-29 2015-08-05 Helsinn Healthcare S.A. Crystal forms of (3R)-1-(2-methylalanyl-D-tryptophyl)-3-(phenylmethyl)-3-piperidinecarboxylic acid 1,2,2-trimethylhydrazide
CA2677813A1 (en) * 2007-02-13 2008-08-21 Helsinn Therapeutics (U.S.), Inc. Method of treating cell proliferative disorders using growth hormone secretagogues
TWI429436B (zh) 2007-04-10 2014-03-11 Helsinn Therapeutics Us Inc 使用生長激素促泌素治療或預防嘔吐之方法
JO3353B1 (ar) 2012-04-20 2019-03-13 Ono Pharmaceutical Co شكل صلب معزول من أحادي هيدروكلوريد أناموريلين بنسبة مولارية منخفضة من الكلوريد: أناموريلين ومحتوى منخفض من مذيب عضوي متبقي
EP2854810A4 (en) 2012-05-25 2016-04-06 Raqualia Pharma Inc GHRELIN RECEPTOR AGONISTS FOR THE TREATMENT OF ACHLORHYDRIA
DK3188599T3 (da) 2014-09-04 2019-11-25 Helsinn Healthcare Sa Medicinske behandlinger baseret på anamorelin

Also Published As

Publication number Publication date
CN109172575A (zh) 2019-01-11
SI3188599T1 (sl) 2020-02-28
EA035578B1 (ru) 2020-07-09
GEP20186939B (en) 2018-12-25
JP2018154655A (ja) 2018-10-04
KR20180085047A (ko) 2018-07-25
ECSP17019893A (es) 2017-05-31
PE20171109A1 (es) 2017-08-07
KR20210035923A (ko) 2021-04-01
RS59751B1 (sr) 2020-02-28
AU2015312231A1 (en) 2017-03-23
IL250692B (en) 2019-05-30
US20210093627A1 (en) 2021-04-01
US20170296526A1 (en) 2017-10-19
JP7044918B2 (ja) 2022-03-30
JP2021080281A (ja) 2021-05-27
PH12017500392B1 (en) 2018-08-31
UA120765C2 (uk) 2020-02-10
EP3188599B1 (en) 2019-10-02
HUE046894T2 (hu) 2020-04-28
LT3188599T (lt) 2019-12-10
DOP2017000055A (es) 2017-08-15
MD20170025A2 (ro) 2017-07-31
TN2017000040A1 (en) 2018-07-04
CN113577073A (zh) 2021-11-02
WO2016036598A1 (en) 2016-03-10
CL2017000494A1 (es) 2017-09-15
IL250692A0 (en) 2017-04-30
CY1122746T1 (el) 2021-03-12
CN113577074A (zh) 2021-11-02
KR101881264B1 (ko) 2018-07-23
MD4710C1 (ro) 2021-04-30
KR20170047372A (ko) 2017-05-04
US11723902B2 (en) 2023-08-15
EP3188599A1 (en) 2017-07-12
JP2017526695A (ja) 2017-09-14
JP6356907B2 (ja) 2018-07-11
US10278964B2 (en) 2019-05-07
US20240024303A1 (en) 2024-01-25
KR102307275B1 (ko) 2021-09-30
EP3590338A2 (en) 2020-01-08
MX361741B (es) 2018-12-14
EP3188599A4 (en) 2017-10-11
KR102234319B1 (ko) 2021-04-01
CN107375285A (zh) 2017-11-24
AP2017009772A0 (en) 2017-02-28
MA40607B1 (fr) 2019-11-29
DK3188599T3 (da) 2019-11-25
EA201790352A1 (ru) 2017-07-31
UY36286A (es) 2016-02-29
PL3188599T3 (pl) 2020-06-01
HRP20192345T1 (hr) 2020-03-20
EP3590338A3 (en) 2020-03-18
TWI639429B (zh) 2018-11-01
BR112017003552A2 (pt) 2017-12-05
ES2761777T3 (es) 2020-05-21
NI201700024A (es) 2017-07-18
PH12017500392A1 (en) 2017-07-17
JO3541B1 (ar) 2020-07-05
US9675600B2 (en) 2017-06-13
SG11201701567UA (en) 2017-03-30
MY187167A (en) 2021-09-07
US20190175574A1 (en) 2019-06-13
NZ729673A (en) 2023-09-29
CO2017003263A2 (es) 2017-07-28
MX2017002825A (es) 2017-09-28
SV2017005400A (es) 2017-04-20
TW201613587A (en) 2016-04-16
CN107205389A (zh) 2017-09-26
AR103118A1 (es) 2017-04-19
GEAP201814459A (en) 2018-09-10
AU2015312231B2 (en) 2017-10-19
PT3188599T (pt) 2020-01-15
US20160067236A1 (en) 2016-03-10
JP6923486B2 (ja) 2021-08-18
MD4710B1 (ro) 2020-09-30
ME03597B (me) 2020-07-20
US10894041B2 (en) 2021-01-19
CA2959158A1 (en) 2016-03-10

Similar Documents

Publication Publication Date Title
MX361741B (es) Tratamientos médicos a base de anamorelina.
TWD196868S (zh) 超音波治療手持件
TWD192896S (zh) 按摩器
CL2018001677A1 (es) Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert
CO6450651A2 (es) Terapia complementaria contra el cancer
MX2017006938A (es) Terapia de combinacion para el tratamiento de cancer.
EA201691656A2 (ru) Терапевтические способы с применением норибогаина и родственных соединений
MX379359B (es) Derivados de 8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano.
MX2018008640A (es) Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]- decano.
HK1243368A1 (zh) 丁丙诺啡给药方案
UA118474C2 (uk) (s)-пірліндол та його фармацевтично прийнятні солі для застосування в медицині
EA201071209A1 (ru) Применение дронедарона или его фармацевтически приемлемой соли для получения лекарственного средства для регуляции уровня калия в крови
MX2022007738A (es) Procesos e intermedios sinteticos.
MX2025002392A (es) Formulaciones de dantroleno y metodos de uso de dichas formulaciones
MX369090B (es) Sultiame para el tratamiento de apnea del sueño.
PH12019501358A1 (en) Methods of administering hepcidin
MY174186A (en) Use of an isopropanol-containing solution to combat caliciviridae
GT201700041A (es) Tratamientos médicos a base de anamorelina
MX2017008516A (es) Anestesico a base de tetracaina.
EA201890019A1 (ru) Способ профилактики недостаточности трансплантата у реципиента
EA201991866A1 (ru) Комбинированная терапия
RU2015109209A (ru) Способ количественной оценки зубочелюстно-лицевых аномалий
Fabiny Ask the doctor. I recently took antibiotics to treat an oral infection and as a result developed a vaginal yeast infection. Can I treat it myself, and what are the most effective options?
EA201692163A1 (ru) Лекарственное средство для лечения пациентов с тиннитусом
EA201990553A1 (ru) Применение придопидина для лечения ухудшения функциональной способности